U.S. flag An official website of the United States government

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Malladi Drugs & Pharmaceuticals Ltd. - 541915 - 01/31/2023
  1. Warning Letters

CLOSEOUT LETTER

Malladi Drugs & Pharmaceuticals Ltd. MARCS-CMS 541915 —

Reference #:
3005115135
Product:
Drugs
Recipient:
Recipient Name
Mr. V.N. Gopalkrishnan
Recipient Title
Co-Founder & Chairman
Malladi Drugs & Pharmaceuticals Ltd.

SKCL Tech Square, 7th Floor, Plot No.: South Phase 14
Thiru Vi Ka Industrial Estate
Guindy, Chennai 600032
Tamil Nadu
India

Issuing Office:
Center for Drug Evaluation and Research | CDER

United States

Dear Mr. Gopalkrishnan:

The Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our Warning Letter 320-18-40 dated March 09, 2018.

Based on our evaluation, it appears that you have addressed the deviations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority.

The FDA expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should deviations be observed during a subsequent inspection or through other means.


Sincerely,
/S/
Frank Wackes
Compliance Officer
Division of Drug Quality II

 
Back to Top